This clinical trial focuses on patients with coronary artery disease who undergo coronary artery bypass grafting (CABG), a surgery that improves blood flow to the heart by creating new pathways around blocked arteries. The study aims to compare different approaches to preventing graft failure after surgery using blood-thinning medications.
The study examines three different treatment combinations: acetylsalicylic acid (also known as aspirin) at a low dose (75 mg) plus prasugrel (10 mg), aspirin alone at a high dose (300 mg), or aspirin alone at a low dose (75 mg). These medications help prevent blood clots from forming in the newly created bypass grafts. The treatment period with these specific combinations lasts for three months, after which all patients continue with low-dose aspirin only.
The research will track how well the bypass grafts remain open over time and monitor for complications such as bleeding, heart attacks, or the need for additional procedures. Patients will be followed for 12 months after their surgery to evaluate the effectiveness and safety of these different medication combinations.



Poland